Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265783 | 0.86 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL21899343 | 0.82 | CDK2 (0.41) | CDK2HDAC1HDAC6 | |
| SCHEMBL22576285 | 0.78 | CDK2 (0.41) | CDK2 | |
| SCHEMBL19510949 | 0.77 | HRH4 (0.40) | CDK2HDAC1HDAC6 | |
| SCHEMBL4265784 | 0.77 | CYP11B2 (0.34) | CHRNB2CHRNA4 | |
| SCHEMBL16755476 | 0.77 | NOS1 (0.38) | CDK2MAPKAPK2 | |
| SCHEMBL24197378 | 0.76 | HDAC1 (0.32) | CDK2HDAC1HDAC6 | |
| SCHEMBL19510633 | 0.74 | CDK2 (0.39) | CDK2 | |
| SCHEMBL16369766 | 0.74 | CDK2 (0.41) | CDK2 | |
| SCHEMBL22616936 | 0.73 | KCNH2 (0.46) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CDK2 124/4885MAPKAPK2 93/4885CHRNB2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.